REGN · Regeneron Pharmaceuticals

432 filings

REGN SEC Filings

Regeneron Pharmaceuticals - 432 total filings

Filing record · 2016–202610-K1110-Q338-K115

Showing 1–50 of 432 filings

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 30, 2026)

Regeneron Pharmaceuticals, Inc. reported strong third-quarter 2026 financial and operating results, demonstrating robust growth across its key product lines and pipeline advancements. Total revenues surged by 36% year-over-year to $5.1 billion, driven by significant increases in Dupixent, EYLEA HD, and Libtayo sales. This top-line growth translated into substantial bottom-line improvements, with GAAP EPS rising 35% to $18.45 and non-GAAP EPS jumping 70% to $20.07. The company also highlighted progress in its pipeline, including the FDA approval of Pasatru™ (garetosmab) for fibrodysplasia ossificans progressiva (FOP) and positive developments for Libtayo's dosing schedule and indications. Furthermore, Regeneron expanded its collaboration with Sanofi, securing a $1.0 billion upfront payment and potential for additional milestones, signaling confidence in future long-acting immunology antibody developments. These results position Regeneron for a strong year and underscore the continued commercial success and pipeline productivity of the company.

Oct 30, 2026 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q3 Ended Sep 30, 2026

Regeneron Pharmaceuticals, Inc. reported strong financial results for the nine months ended September 30, 2026, with revenues reaching $13.01 billion, a significant increase from $10.46 billion in the prior year period. Net income also saw robust growth, reaching $3.97 billion compared to $3.66 billion in the same period last year. This performance was driven by strong net product sales, particularly from EYLEA HD and Libtayo, and a substantial increase in collaboration revenue, notably from the Sanofi partnership. The company's strategic collaborations, including the significant amendment with Sanofi in October 2026, which includes an upfront payment of $1 billion and potential future milestone payments, continue to be key drivers of growth. Despite ongoing legal proceedings and competitive pressures, especially for EYLEA, Regeneron demonstrates a healthy financial position and a robust pipeline. The balance sheet as of September 30, 2026, shows total assets of $44.4 billion, an increase from $40.56 billion at the end of 2025, supported by healthy cash and cash equivalents and growing accounts receivable. Stockholders' equity also increased, reflecting strong retained earnings and additional paid-in capital, despite significant share repurchases and dividend payments. The company generated substantial cash flow from operations, providing ample liquidity to fund its ongoing research and development activities, capital expenditures, and shareholder returns.

Oct 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Material Agreement (Oct 6, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing a significant amendment to its existing License and Collaboration Agreement (LCA) with Sanofi. This Sixth Amendment focuses on the co-development and co-commercialization of four novel, Regeneron-invented long-acting antibodies targeting key inflammatory pathways (IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13). This strategic move significantly expands Regeneron's pipeline in high-potential therapeutic areas. The financial implications for Regeneron are substantial. Sanofi will provide an upfront payment of $1.0 billion, with the potential for an additional $7.0 billion in milestone payments tied to development, regulatory, and commercial success. This partnership also includes a balanced approach to cost-sharing for development, with Regeneron acting as the lead development and regulatory party in the U.S. Additionally, the report discloses an expected $22 million pre-tax acquired in-process R&D charge for Q3 2026, impacting EPS by approximately $0.18. The settlement of a prior lawsuit regarding Dupixent commercialization information is also a notable event.

Oct 6, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Sep 30, 2026)

Regeneron (REGN) filed an 8-K on September 30, 2026 disclosing two governance and compensation actions. First, effective September 24, 2026, the Compensation Committee, with approval from independent directors, granted co-founders Leonard Schleifer (CEO) and George Yancopoulos (CSO) a one-time, 100% performance-based award of performance share units (2026 PSUs) under the 2014 Long-Term Incentive Plan. The awards replace annual long-term incentive grants for both executives through 2036, run over a 10-year performance period (2026–2035), and carry a mandatory holding period into February 2036. Payouts depend on new product filings and approvals (smaller earnout) and new product revenues (the largest earnout), with a relative TSR modifier of up to ±20% against the NASDAQ Biotechnology Index. Hard caps are 2.7 million PSUs for the CEO and 2.9 million for the CSO, and the maximum earnout requires roughly $30 billion in annual new-product revenue, about double Regeneron's 2025 total revenue. Second, the Company formed a New Subsidiary to explore a potential non-core business. Both executives received partially vesting equity stakes in it. The company describes the entity as nominal in value, without significant assets, not yet operating, and possibly never pursuing the opportunity. Its financial impact appears immaterial at this stage. For investors, the key points are the alignment of the co-founders' pay with long-term pipeline and commercial delivery, and the design choices shaped by shareholder engagement, including the heavier weighting toward revenue and the succession planning requirement. Retention risk is reduced because forfeiture applies on voluntary departure. Dilution and expense are a consideration, though the filing does not quantify the grant-date fair value or the dilutive effect of the awards.

Sep 30, 2026 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q2 Ended Jun 30, 2026

Regeneron Pharmaceuticals, Inc. reported solid financial results for the second quarter and first half of 2026, demonstrating continued revenue growth driven primarily by its collaboration with Sanofi, particularly strong performance from Dupixent. Total revenues increased by 15.2% for the quarter and 17.6% for the six months, reaching $4,290.7 million and $7,896.1 million respectively. Net income for the quarter was $1,296.9 million, a slight decrease from the prior year's $1,391.6 million, resulting in diluted earnings per share of $12.23, down from $12.81. For the first half of the year, net income was $2,024.1 million, a decrease from $2,200.3 million in the prior year, with diluted EPS of $18.95 compared to $20.02. Despite the slight dip in profitability on a per-share basis, the company's balance sheet remains strong, with total assets growing to $41.7 billion. The company continued its commitment to shareholder returns through dividends and share repurchases, signaling confidence in its future performance.

Jul 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 30, 2026)

Regeneron reported second quarter 2026 results on July 30, 2026, with total revenues up 17% year over year to $4.29 billion and non-GAAP EPS up 11% to $14.29, marking a second consecutive quarter of double-digit growth on both top and bottom lines. Growth was driven largely by the Sanofi collaboration, where Regeneron's share of antibody profits rose to $2.03 billion from $1.28 billion on higher Dupixent sales (global Dupixent sales up 38% to $6.0 billion). U.S. EYLEA HD sales grew 52% to $596 million and Libtayo global sales rose 30% to $489 million, while legacy U.S. EYLEA fell 45% as patients transition to EYLEA HD. GAAP EPS was $12.23, reflecting a $1.02 per share hit from acquired IPR&D charges, and GAAP EPS declined 5% year over year. Management highlighted that the Sanofi Development Balance was fully repaid by the end of the second quarter, which removes a reduction to Sanofi collaboration revenue starting in the third quarter and should meaningfully lift collaboration profits. Gross margin on net product sales was pressured by a temporary interruption of bulk manufacturing at the Limerick, Ireland facility, though production has returned to normal levels. The company raised the midpoint of several 2026 non-GAAP guidance items, including non-GAAP gross margin (now 84%-85%) and non-GAAP R&D, while lowering capital expenditure guidance to $1.03-$1.10 billion. Capital returns remain significant, with $2.0 billion of share repurchases in the first half and a $0.94 quarterly dividend declared. Pipeline news was mixed. The Phase 3 fianlimab plus cemiplimab melanoma trial missed its primary PFS endpoint, while cemdisiran was accepted for review in gMG by both the FDA (priority review, target action date November 2026) and the EMA. Investors should also note that the balance sheet shows cash and marketable securities declining to $17.8 billion from $18.9 billion, and the company's own results include forward-looking caveats tied to Sanofi and Bayer collaboration dependence, EYLEA competition, and pending DOJ-related litigation.

Jul 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 6, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 million. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter. Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.

Jul 6, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 17, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 17, 2026, detailing the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. The report confirms the election of Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, shareholders provided advisory approval for executive compensation. Key outcomes include the successful election of all nominated directors, indicating strong shareholder confidence in the current board's leadership. The ratification of the auditor received substantial support, reinforcing the company's commitment to financial transparency and robust auditing practices. The advisory vote on executive compensation also passed with a significant majority, suggesting shareholder alignment with the company's compensation philosophy for its named executive officers.

Jun 17, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 29, 2026)

Regeneron reported first quarter 2026 results that showed strong top-line and earnings growth, with total revenues up 19% to $3.605 billion and non-GAAP diluted EPS up 15% to $9.47. GAAP diluted EPS was $6.75, down 7% year over year, reflecting $0.82 of acquired IPR&D charges and $0.80 of IPR&D impact on non-GAAP results, plus a temporary manufacturing interruption at the Limerick, Ireland facility. Growth was driven largely by Sanofi collaboration revenue (up 36%, with Dupixent global sales up 33% to $4.9 billion), while U.S. EYLEA HD sales rose 52% to $468 million, though combined EYLEA HD and EYLEA U.S. sales fell 10% to $941 million as patients transition to EYLEA HD and competition intensifies. Key regulatory and pipeline events included FDA approvals for EYLEA HD extended dosing up to every 20 weeks, Dupixent in pediatric CSU and allergic fungal rhinosinusitis, and Otarmeni, a gene therapy for OTOF-related hearing loss that Regeneron will provide free in the U.S. A notable overhang is the EYLEA HD pre-filled syringe, where the FDA has not yet acted on a PDUFA date for a second filler, with a decision expected in Q2 2026. Phase 3 fianlimab melanoma data are due in Q2 2026, while the NSCLC program was dropped from Phase 3 advancement. Capital allocation remained shareholder-friendly, with $803 million of buybacks in the quarter, a new $3.0 billion repurchase authorization, and a $0.94 quarterly dividend. Management trimmed 2026 capex guidance to $1.1–$1.2 billion and lowered its GAAP gross margin guidance to 77%–78% due to the Limerick disruption, while leaving most other guidance unchanged. The company also announced an April 2026 agreement with the U.S. government on Most-Favored-Nation drug pricing, with a three-year tariff relief provision in return.

Apr 29, 2026 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q1 Ended Mar 31, 2026

Regeneron Pharmaceuticals, Inc. reported solid top-line growth in the first quarter of 2026, with total revenues increasing by approximately 19% year-over-year to $3.61 billion. This growth was primarily driven by a substantial increase in collaboration revenue, largely from the Sanofi collaboration, which saw a significant uptick in Dupixent and Kevzara sales. Despite overall revenue growth, net income experienced a decline of approximately 10% to $727.2 million, leading to a decrease in diluted earnings per share to $6.75 from $7.27 in the prior year period. This was influenced by a significant increase in operating expenses, particularly in research and development and cost of goods sold. The company also continued its aggressive share repurchase program and declared a quarterly dividend, indicating a focus on returning value to shareholders. Investors will be closely watching the company's efforts to navigate competitive pressures in key franchises like EYLEA and the ongoing legal matters. Regeneron's balance sheet remains robust, with total assets increasing and a healthy working capital position. The company generated significant cash flow from operations. However, an increase in current liabilities, notably due to a significant finance lease liability, warrants attention. The company also provided updated guidance on expected capital expenditures for the full year 2026, indicating continued investment in infrastructure.

Apr 29, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 8, 2026)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose anticipated financial results for the first quarter of 2026. The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis. This charge is primarily associated with equity securities purchased and payments made under collaboration and licensing agreements. The most significant impact for investors is the expected negative effect of this IPR&D charge on both GAAP and non-GAAP net income per diluted share, estimated at $0.81 for the first quarter of 2026. It's important to note that these are preliminary estimates, subject to finalization of financial closing procedures, and actual results could differ. The company also highlighted that acquired IPR&D charges are inherently unpredictable and not typically forecasted.

Apr 8, 2026 10-K

Regeneron Pharmaceuticals Annual Report, Year Ended Dec 31, 2025

Regeneron's FY2025 10-K shows revenue of $14.34B (up about 1% from $14.20B in 2024) and net income of $4.50B, with diluted EPS of $41.48 versus $38.34. Growth came from collaboration revenue, especially Sanofi (up 30% to $5.88B, driven by Dupixent), which offset a 17% decline in net product sales to $6.31B. Net product sales fell because U.S. EYLEA sales dropped 42% to $2.75B on biosimilar competition, compounded bevacizumab substitution, and patient migration to EYLEA HD. Operating income fell to $3.58B from $3.99B as R&D rose 14% to $5.85B, partly due to a $155M priority review voucher expense. Net income was lifted by $1.65B in other income, mainly $946M of securities gains and $717M of interest income. Concentration risk is high. EYLEA HD and EYLEA made up 31% of 2025 revenue, down from 42% in 2024, and Dupixent-related Sanofi revenue made up 41%, up from 32%. Two distributor customers accounted for 77% of gross product revenue. The balance sheet is strong, with $18.9B in cash and marketable securities against $2.7B of debt and finance leases. The company initiated a quarterly dividend of $0.88 in 2025, raised it to $0.94 for 2026, and repurchased $3.46B of stock. Near-term catalysts include FDA decisions on the EYLEA HD pre-filled syringe (Q2 2026) after an October 2025 CRL tied to a third-party filler, and on the Dupixent AFRS sBLA (February 2026). Additional items include the bullous pemphigoid EC decision, the cemdisiran myasthenia gravis NDA, and readouts for fianlimab and garetosmab. Biosimilar EYLEA entries are being settled ex-U.S. on dated timelines, and the Sanofi and Amgen litigation remains unresolved.

Feb 4, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 30, 2026)

Regeneron reported fourth quarter and full year 2025 results on January 30, 2026, with modest top-line growth driven by strong Dupixent economics offset by continued erosion of EYLEA. Q4 2025 total revenues rose 3% to $3.88 billion, and full year revenues rose 1% to $14.34 billion. GAAP EPS was $7.86 in Q4 (down 2%) and $41.48 for the full year (up 8%), while non-GAAP EPS was $11.44 in Q4 (down 5%) and $44.31 for the year (down 3%). Full-year GAAP net income of $4.5 billion was lifted by $946 million of securities gains, and non-GAAP net income declined 8% to $4.9 billion. The key story is the divergence between partner-driven and U.S. franchise performance. Dupixent global net sales (recorded by Sanofi) grew 26% for the year to $17.8 billion, and Regeneron's share of antibody profits from Sanofi rose to $5.2 billion, which is now the company's main revenue engine. In contrast, total U.S. EYLEA HD and EYLEA net sales fell 27% to $4.4 billion as legacy EYLEA lost volume to competition and compounded bevacizumab, partly offset by 36% growth in EYLEA HD to $1.6 billion. Non-GAAP gross margin on net product sales compressed to 85% from 88%, and R&D spending rose 13% on a non-GAAP basis. Looking ahead, management guided 2026 non-GAAP R&D to $5.9–6.1 billion, non-GAAP SG&A to $2.5–2.65 billion, and capital expenditures to $1.1–1.3 billion, and it excludes unannounced business development deals. The company declared a $0.94 per share dividend and had $1.5 billion remaining under its buyback authorization, after repurchasing $3.5 billion of stock in 2025. Near-term catalysts include an FDA decision on the EYLEA HD pre-filled syringe and DB-OTO in the first half of 2026, an AFRS sBLA decision in February 2026, and Phase 3 readouts for fianlimab and cemdisiran in 2026.

Jan 30, 2026 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 12, 2026)

Regeneron (REGN) filed this 8-K on January 12, 2026, furnishing a J.P. Morgan Healthcare Conference presentation by CEO Leonard Schleifer and CSO George Yancopoulos. The filing is primarily a corporate update with preliminary, unaudited Q4 and full-year 2025 information that remains subject to closing procedures. Two discrete items were disclosed: an acquired in-process R&D (IPR&D) charge of approximately $19 million pre-tax in Q4 2025, which reduces both GAAP and non-GAAP diluted EPS by about $0.14, and an approximately $60 million matching contribution to the Good Days Retinal Vascular and Neovascular Disease Fund, recorded in SG&A. The presentation shows strong commercial momentum. Dupixent global net sales were $736M in Q4 2025 per the slide, and EYLEA HD physician demand grew 10% quarter over quarter. Management noted that Q4 EYLEA HD and EYLEA U.S. net sales were each favorably impacted by roughly $30 million from higher wholesaler inventory, so underlying demand is somewhat lower than reported. Management also reported capital returns of about $3.8 billion in 2025 (roughly $3.4 billion in buybacks and $0.4 billion in dividends), with a quarterly dividend of $0.88 per share initiated in 2025 and about $1.5 billion remaining under the repurchase authorization. Projected 2026 non-GAAP R&D spend is above $7 billion, and GAAP R&D is estimated at about $6.5 billion. For investors, the filing's near-term catalysts are concentrated in 1H 2026: pivotal fianlimab plus cemiplimab data in first-line metastatic melanoma, a DB-OTO FDA decision, an EYLEA HD pre-filled syringe decision in 2Q 2026, and several Factor XI and obesity Phase 3 starts. Formal 2026 financial guidance was deferred to the Q4 2025 earnings release. The filing also flags pending DOJ-related litigation and EYLEA patent litigation as risk factors.

Jan 12, 2026 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q3 Ended Sep 30, 2025

Regeneron Pharmaceuticals, Inc. reported strong financial results for the nine months ended September 30, 2025, with total revenues of $10.46 billion, a slight increase from the same period in 2024. Net income also saw a positive trend, reaching $3.66 billion, up from $3.49 billion in the prior year. Diluted earnings per share were $33.61, an increase from $30.23. The company's product sales, while experiencing a decline in EYLEA revenue due to increased competition and the transition to EYLEA HD, were bolstered by significant growth in Dupixent and Libtayo sales. Collaboration revenue, primarily from Sanofi, also showed robust growth, driven by strong Dupixent performance. Operating expenses increased due to higher R&D investments, particularly in direct R&D for key programs, though SG&A expenses decreased. The company continued its share repurchase program and declared regular quarterly dividends, underscoring a commitment to returning capital to shareholders.

Oct 28, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 28, 2025)

Regeneron reported third quarter 2025 results with total revenues up 1% year-over-year to $3.75 billion, but the top line masks a sharp shift in mix. U.S. EYLEA sales fell 41% to $681 million as patients moved to EYLEA HD and faced biosimilar and compounded bevacizumab pressure, while Dupixent (recorded by Sanofi) grew 27% to $4.86 billion globally, lifting Regeneron's share of collaboration profits to $1.46 billion. GAAP EPS was $13.62 versus $11.54 a year ago, helped by $578 million of securities gains, while non-GAAP EPS fell 5% to $11.83 and was reduced by a $0.68 acquired IPR&D charge. Non-GAAP net income declined 12% to $1.29 billion, so the GAAP beat is largely non-operating in nature. Pipeline and regulatory news was mixed. Libtayo received FDA approval as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma, and positive Phase 3 data were reported in generalized myasthenia gravis, FOP, and cat and birch allergies. Management also disclosed a setback: the FDA issued a Complete Response Letter for the EYLEA HD pre-filled syringe sBLA, citing unresolved inspection findings at contract filler Catalent, and the company plans to resubmit with a new filler by January 2026. Other near-term catalysts include an EYLEA HD every-four-week dosing and RVO decision expected in late November 2025 and a DB-OTO filing planned for Q4 2025 with a National Priority Voucher. Financially, the company returned over $3 billion to shareholders in the first nine months through buybacks and dividends, with $2.156 billion remaining authorization. Management lowered full-year 2025 non-GAAP R&D and SG&A guidance and raised the GAAP effective tax rate to about 14% due to a $45 million charge from the One Big Beautiful Bill Act. Free cash flow for the nine months was $3.16 billion, up from $2.60 billion. Investors should weigh the EYLEA franchise erosion and manufacturing-related regulatory risk against Dupixent-driven collaboration income and a strong balance sheet.

Oct 28, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 6, 2025)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis for the third quarter of 2025. This charge is primarily linked to an $80 million upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.

Oct 6, 2025 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q2 Ended Jun 30, 2025

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the quarter and six months ended June 30, 2025. Total revenues for the six months ended June 30, 2025, were $6.704 billion, a slight increase from $6.692 billion in the same period of 2024. Net income for the first six months of 2025 was $2.200 billion, or $20.02 per diluted share, compared to $2.154 billion, or $18.68 per diluted share, in the prior year's period. The company's balance sheet shows total assets of $38.219 billion as of June 30, 2025, and total stockholders' equity of $29.939 billion. The company saw a decrease in net product sales, primarily driven by a significant decline in EYLEA sales, which was partially offset by growth in EYLEA HD and Dupixent. Collaboration revenues, largely from the Sanofi and Bayer partnerships, showed a substantial increase, driven by higher profit shares, particularly from Dupixent. Operating expenses, notably research and development, increased year-over-year, reflecting continued investment in the company's pipeline. Investors should note the ongoing legal proceedings related to EYLEA biosimilar challenges and the company's active share repurchase program, which repurchased approximately $2.122 billion of common stock during the first six months of 2025. The company also declared and paid quarterly dividends.

Aug 1, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 1, 2025)

Regeneron reported second quarter 2025 results on August 1, 2025, with total revenues up 4% to $3.68 billion and GAAP EPS up 3% to $12.81 (non-GAAP EPS up 12% to $12.89). Growth was driven by Dupixent, where Regeneron's share of antibody profits rose to $1.28 billion, and by U.S. EYLEA HD sales, which grew 29% to $393 million. These gains were offset by a 39% decline in U.S. EYLEA sales to $754 million, reflecting competitive pressure, share loss to compounded bevacizumab, and patient transition to EYLEA HD. Total EYLEA HD and EYLEA U.S. sales fell 25% to $1.15 billion. The quarter also brought several regulatory and pipeline developments. The FDA approved Lynozyfic for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and CSU, and accepted a Libtayo adjuvant CSCC sBLA for priority review with an October 2025 target action date. Offsetting these, the FDA issued a Complete Response Letter for odronextamab on July 30, and the company expects delays for pending EYLEA HD FDA applications with August 2025 PDUFA dates. Both issues trace to an FDA inspection at Catalent Indiana, a filler now owned by Novo Nordisk. In addition, the Phase 3 AERIFY-2 trial for itepekimab in COPD missed its primary endpoint, while AERIFY-1 met it. Management raised its 2025 GAAP R&D and GAAP SG&A guidance ranges and narrowed or lowered several other items, while raising the GAAP effective tax rate guidance to 11%-13%. The company returned over $2.3 billion to shareholders in the quarter through buybacks and dividends, with $2.81 billion remaining under its repurchase authorization. Second quarter GAAP net income declined 3% to $1.39 billion, helped by $250 million of unrealized equity-security gains that flatter results relative to operating performance.

Aug 1, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 18, 2025)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing the outcomes of its 2025 Annual Meeting of Shareholders held on June 13, 2025. The key takeaways for investors revolve around significant governance changes and shareholder confidence in the company's direction and leadership. Shareholders overwhelmingly re-elected all Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025, indicating strong support for the current board and financial oversight. Furthermore, investors approved an advisory vote on executive compensation, demonstrating confidence in the company's compensation practices. A notable governance shift occurred with the approval to declassify the board of directors, moving towards a more standard annual election of all board members. However, proposals to eliminate certain supermajority vote requirements for specific charter amendments did not pass, suggesting a desire among some shareholders for existing protections or a cautious approach to altering these provisions.

Jun 18, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 29, 2025)

Regeneron reported first quarter 2025 results on April 29, 2025, with total revenues of $3.03 billion (down 4% year over year) and GAAP diluted EPS of $7.27 (up 16%), while non-GAAP diluted EPS fell 14% to $8.22. The top-line decline was driven by EYLEA, where combined EYLEA HD and EYLEA U.S. net sales fell 26% to $1.04 billion as legacy EYLEA lost volume to biosimilars, compounded bevacizumab, and the transition to EYLEA HD. EYLEA HD U.S. sales grew 54% to $307 million, a bright spot, but not enough to offset the legacy decline. Partly offsetting this, Sanofi collaboration revenue rose 30% to $1.18 billion on higher Dupixent sales, which grew 19% globally to $3.67 billion. The quarter also brought mixed regulatory news. Dupixent was approved in the U.S. for chronic spontaneous urticaria, and EYLEA HD received a Complete Response Letter for its pre-filled syringe, tied to a third-party component supplier, and a separate CRL limiting extended dosing intervals to no longer than every 16 weeks. Management kept full-year 2025 R&D and SG&A guidance unchanged, lowered GAAP and non-GAAP gross margin guidance, and narrowed capital expenditure guidance. Capital returns continued with $1.05 billion in Q1 buybacks, $3.87 billion of remaining authorization, and a first-time $0.88 per share dividend declared for June payment. For investors, the key issues are whether EYLEA HD growth can offset legacy erosion, the timing of the EYLEA HD syringe and dosing resubmissions, gross margin pressure from inventory write-offs, and the cadence of pipeline readouts expected later in 2025.

Apr 29, 2025 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q1 Ended Mar 31, 2025

Regeneron Pharmaceuticals, Inc. reported mixed results for the first quarter of 2025. Total revenues decreased slightly year-over-year to $3.03 billion from $3.15 billion, primarily driven by a significant decline in U.S. EYLEA sales due to competitive pressures and the transition to EYLEA HD. However, this was partially offset by strong growth in Dupixent and a solid performance from EYLEA HD in the U.S. Net income increased to $808.7 million, or $7.27 per diluted share, compared to $722.0 million, or $6.27 per diluted share, in the prior year's quarter. This improvement was supported by an increase in collaboration revenue, particularly from Sanofi, and a favorable shift in other income (expense), net. The company also announced its first quarterly cash dividend and continued its share repurchase program, signaling a commitment to returning capital to shareholders.

Apr 29, 2025 10-K

Regeneron Pharmaceuticals Annual Report, Year Ended Dec 31, 2024

Regeneron (REGN) reported record 2024 results: total revenues rose 8% to $14.20 billion (from $13.12 billion), and net income grew 12% to $4.41 billion, with diluted EPS of $38.34 (up from $34.77). Growth was driven primarily by collaboration revenue, especially Sanofi's share of Dupixent profits ($4.53 billion, up 19%), and by Dupixent global sales, which reached $14.1 billion. Other drivers included Libtayo global sales of $1.22 billion (up 41%) and EYLEA HD's U.S. launch, which generated $1.20 billion in its first full year. Offsetting these gains, U.S. EYLEA sales fell 17% as biosimilar competition arrived after the May 2024 exclusivity expiry, and U.S. EYLEA HD and EYLEA combined net sales rose only 1% to $5.97 billion. Profitability was pressured by higher operating expenses, which rose 13% to $10.21 billion, driven by R&D of $5.13 billion (up 16%) and SG&A of $2.95 billion (up 4%) tied to the EYLEA HD launch and international expansion. Income from operations declined about 1% to $3.99 billion. Net income was supported by $844 million in other income, mainly $711 million of interest income, and by a low 7.7% effective tax rate. Cash generation stayed strong at $4.42 billion of operating cash flow, though free cash flow was lower after $756 million of capex. Cash and marketable securities totaled $17.9 billion against $2.7 billion of debt and finance lease obligations. Management signaled a shift in capital return policy: the board authorized a new $3.0 billion buyback in February 2025 and initiated a quarterly dividend of $0.88 per share, a first for the company. Investors should weigh concentration risk: EYLEA franchise and Dupixent together account for a large share of revenue, and the company faces significant legal exposure, including DOJ False Claims Act and Anti-Kickback matters related to EYLEA, Praluent antitrust litigation, and a new securities class action. Capital expenditures are expected to be $850 million to $975 million in 2025, and the pipeline includes several 2025 regulatory decisions, such as linvoseltamab, Dupixent CSU, and EYLEA HD for RVO.

Feb 5, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Feb 4, 2025)

Regeneron reported strong fourth quarter and full year 2024 results on February 4, 2025, with total revenues rising 10% to $3.79 billion in Q4 and 8% to $14.20 billion for the full year. Growth was driven largely by Dupixent, whose global net sales (recorded by Sanofi) rose 22% for the year to $14.15 billion, lifting Regeneron's share of antibody profits from Sanofi collaboration revenue to $3.92 billion. EYLEA HD continued its launch trajectory, contributing $1.20 billion in full-year U.S. sales, while combined U.S. EYLEA HD and EYLEA sales grew only 1% as legacy EYLEA declined 17% for the year and net selling prices fell. Libtayo grew 40% to $1.22 billion. GAAP diluted EPS was $38.34 for the year (up 10%), and non-GAAP EPS was $45.62 (up 4%); Q4 GAAP EPS of $8.06 was down 21%, weighed by $213 million of unrealized losses on equity securities. Capital allocation was the headline announcement. Regeneron initiated its first quarterly cash dividend of $0.88 per share, payable March 20, 2025 to holders of record on February 20, 2025, and authorized an additional $3.0 billion share repurchase program, bringing total repurchase capacity to roughly $4.5 billion. The company repurchased $2.6 billion of stock in 2024, including $976 million in Q4, and reported free cash flow of $3.66 billion for the year. Management frames the dividend as an ongoing quarterly commitment subject to board discretion and market conditions. For 2025, the company issued detailed guidance, including non-GAAP R&D of $5.00–$5.20 billion, non-GAAP SG&A of $2.55–$2.70 billion, a non-GAAP gross margin on net product sales of 87%–88%, and a non-GAAP effective tax rate of 11%–13%. The pipeline calendar features several near-term catalysts, including an sBLA for EYLEA HD in retinal vein occlusion, a Dupixent CSU action date of April 18, 2025, an EYLEA HD two-year data action date of April 20, 2025, and a linvoseltamab FDA decision expected mid-2025.

Feb 4, 2025 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 13, 2025)

Regeneron's January 13, 2025 Form 8-K, furnished under Items 2.02 and 7.01, pairs preliminary (unaudited) fourth-quarter and full-year 2024 results with the company's J.P. Morgan Healthcare Conference presentation. The headline numbers are about $6 billion in aggregate U.S. net sales for EYLEA HD and EYLEA in 2024, up 1% year over year, and Libtayo surpassing $1 billion in 2024 annual net sales. The filing also discloses a fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, which reduces GAAP and non-GAAP diluted EPS by about $0.11. Results are not finalized and remain subject to closing procedures. The pipeline and regulatory updates are the other focus. Libtayo delivered the first statistically significant disease-free survival benefit in high-risk adjuvant cutaneous squamous cell carcinoma (68% risk reduction, HR 0.32), with an FDA submission planned for the first half of 2025. The linvoseltamab BLA was resubmitted with launch expected in mid-2025, and the odronextamab FL BLA resubmission is planned for Q1 2025. Dupixent is now used by over one million patients globally, with a COPD launch underway and a CSU FDA decision due April 18, 2025. Key investor considerations include the EYLEA HD pre-filled syringe launch (mid-2025), the April 20, 2025 PDUFA date for extended EYLEA HD dosing, and 2025 Phase 3 readouts for itepekimab in COPD and fianlimab plus Libtayo in melanoma. The filing also includes standard forward-looking statement cautions and notes that EYLEA HD and EYLEA results were partly boosted by about $85 million of wholesaler inventory build for EYLEA.

Jan 13, 2025 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q3 Ended Sep 30, 2024

Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2024, with total revenues reaching $10.41 billion, an increase of 7.5% compared to the same period in the prior year. Net income also saw a significant rise, up 25% to $3.49 billion. This growth was driven by strong performance across key products, notably Dupixent and EYLEA HD, which showed substantial revenue increases of 25% and approximately 4% respectively in their respective segments. The company also saw positive growth in Libtayo and Praluent. Research and development expenses increased by approximately 14% year-over-year, reflecting continued investment in the company's pipeline. The company ended the period with a strong liquidity position, with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities, while also actively repurchasing shares under its authorized program.

Oct 31, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 31, 2024)

Regeneron reported third quarter 2024 results on October 31, 2024, with total revenues up 11% year over year to $3.72 billion and GAAP diluted EPS up 30% to $11.54 (non-GAAP diluted EPS up 8% to $12.46). Growth was led by Dupixent, whose global net sales recorded by Sanofi rose 23% to $3.82 billion, and by Regeneron's share of antibody profits from Sanofi collaboration, which rose to $1.09 billion from $863 million. Net income was $1.34 billion, helped by $135 million of unrealized gains on equity securities and $187 million of interest income, which flatter GAAP earnings relative to operating income of $1.18 billion. The retinal franchise showed a mixed picture. Combined U.S. EYLEA HD and EYLEA net sales grew only 3% to $1.54 billion, with EYLEA HD contributing $392 million in its first full post-launch comparison period. Standard EYLEA sales fell 21% as lower net selling prices and transition to EYLEA HD eroded the legacy product, and about $40 million of EYLEA HD sales came from higher wholesaler inventory rather than end demand. Libtayo grew 24% to $289 million globally. Management also updated 2024 guidance: GAAP R&D was narrowed, non-GAAP SG&A was lowered at the top end, capital expenditures were cut to $700–740 million, and COCM was raised to $860–900 million. The company repurchased $738 million of stock in the quarter and had $2.9 billion remaining under its authorization. The pipeline news was mostly positive. Dupixent received its first FDA approval as a biologic for COPD with an eosinophilic phenotype, the Chronic Spontaneous Urticaria (CSU) and bullous pemphigoid (BP) trials met their endpoints, and the CSU sBLA was resubmitted. The main setback was an FDA Complete Response Letter for linvoseltamab in multiple myeloma, which was tied to a third-party fill/finish manufacturer inspection and must be resolved before approval in the U.S. or EU.

Oct 31, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 7, 2024)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on October 7, 2024, providing a preliminary update on its expected financial results for the third quarter of 2024. The company anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $56 million on a pre-tax basis. This charge is a result of development milestone and up-front payments tied to collaboration and licensing agreements. This IPR&D charge is projected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43 for the third quarter. Investors should note that these are preliminary estimates, and the actual results are subject to the company's financial statement closing procedures and could differ. Regeneron emphasizes that acquired IPR&D charges are inherently unpredictable due to the uncertainty in timing and magnitude of such transactions, and therefore are not typically forecasted.

Oct 7, 2024 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q2 Ended Jun 30, 2024

Regeneron Pharmaceuticals, Inc. reported strong financial results for the second quarter and first half of 2024, demonstrating robust revenue growth and increased profitability. Total revenues increased by 12% year-over-year for the second quarter to $3.55 billion and by 6% for the first half to $6.69 billion, driven by significant contributions from its key products, particularly Dupixent and EYLEA HD. Net product sales saw a healthy increase, with Dupixent sales up 27% in the second quarter and 26% in the first half. EYLEA HD and EYLEA combined U.S. net sales showed a slight increase of 2%, with EYLEA HD sales contributing $304.2 million in the quarter, reflecting strong patient adoption. Collaboration revenue also saw a substantial increase, primarily due to higher profit shares from Dupixent sales. The company's net income grew significantly, reaching $1.43 billion in the second quarter, a 48% increase year-over-year, resulting in diluted EPS of $12.41. For the first half, net income increased by 21% to $2.15 billion, with diluted EPS of $18.68. The company also continued its share repurchase program, repurchasing $601.4 million in the second quarter, underscoring a commitment to returning capital to shareholders.

Aug 1, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 1, 2024)

Regeneron reported second quarter 2024 results with total revenue up 12% year over year to $3.55 billion, driven by Dupixent (recorded by Sanofi), which grew 27% to $3.56 billion in global net sales, and by notable growth in EYLEA HD and Libtayo. GAAP diluted EPS rose 46% to $12.41, while non-GAAP diluted EPS rose 13% to $11.56. The quarter's GAAP results were flattered by $393 million of unrealized gains on equity securities, so the non-GAAP figures are the better read on core operating performance. Management also highlighted the first European Commission approval of Dupixent for COPD, with a U.S. FDA decision now expected by September 27, 2024 after a three-month extension. The U.S. EYLEA franchise (EYLEA HD plus EYLEA) grew only 2% to $1.53 billion. EYLEA HD contributed $304 million, which offset a sharp 18% decline in legacy EYLEA sales as patients transitioned to the higher-dose product. Operating expenses rose across the board, with SG&A up 16% on EYLEA HD launch costs and COGS up 34% on start-up costs for the Rensselaer fill/finish facility. Full-year 2024 guidance was narrowed, with GAAP R&D and SG&A ranges adjusted and capital expenditure guidance lowered to $750–$820 million. The company ended the quarter with $17.5 billion in cash and marketable securities and repurchased $601 million of stock, with $3.6 billion still authorized. The filing shows a company with strong growth in its immunology franchise, a growing oncology pipeline, and solid balance sheet flexibility. The key watch items for investors are the timing of Dupixent's FDA COPD decision, the pace of EYLEA HD conversion against the legacy EYLEA decline, and the second-half pipeline readouts management flagged.

Aug 1, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 8, 2024)

Regeneron Pharmaceuticals, Inc. has filed a Current Report on Form 8-K to provide preliminary insights into its second quarter 2024 financial results. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $24 million. This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter. While these figures are preliminary and subject to closing procedures, they offer investors an early look at a specific cost impacting the quarter's profitability.

Jul 8, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Shareholder Vote Results (Jun 20, 2024)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report detailing the outcomes of its 2024 Annual Meeting of Shareholders held on June 14, 2024. The primary focus of this filing is the voting results on several key proposals, including the election of directors, ratification of its independent auditor, advisory vote on executive compensation, and a shareholder proposal regarding simple majority voting. All proposals presented to shareholders, with the exception of one, received strong support, indicating continued confidence from the company's investors in its governance and operational direction. Of particular note, all nominated directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was overwhelmingly ratified. The advisory vote on executive compensation also passed. However, a shareholder proposal advocating for simple majority voting requirements also received a majority of the votes cast, suggesting a desire among some shareholders for changes in the company's voting structure. Investors should monitor any subsequent actions or responses from the company regarding this approved shareholder proposal.

Jun 20, 2024 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q1 Ended Mar 31, 2024

Regeneron Pharmaceuticals, Inc. reported a slight decrease in total revenues to $3,145.0 million for the first quarter of 2024, down from $3,162.1 million in the same period last year. This was primarily driven by a decrease in EYLEA net product sales in the U.S., offset by strong growth in Dupixent, Libtayo, and Praluent. Net income saw a decline to $722.0 million from $817.8 million, resulting in diluted EPS of $6.27 compared to $7.17 year-over-year. Despite the revenue dip, the company demonstrated solid operational cash flow generation. Investment in research and development increased significantly, reflecting continued commitment to pipeline expansion. The company also continues its share repurchase program, with $1.233 billion remaining authorization as of March 31, 2024, and authorized an additional $3.0 billion in April 2024.

May 2, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (May 2, 2024)

Regeneron reported first quarter 2024 results on May 2, 2024, with total revenues of $3.15 billion, down 1% year over year, but up 7% excluding Ronapreve collaboration revenue that is not expected to recur. The decline was driven mainly by lower U.S. EYLEA sales (down 16% to $1.20 billion), partly offset by the launch of EYLEA HD ($200 million in its first quarter on market). Growth engines were Dupixent (global sales recorded by Sanofi up 24% to $3.08 billion, flowing through Regeneron's profit share in Sanofi collaboration revenue) and Libtayo (global net sales up 45% to $264 million). Profitability declined: GAAP diluted EPS fell 13% to $6.27 and non-GAAP diluted EPS fell 5% to $9.55, reflecting higher R&D (up 13% GAAP) and SG&A (up 15% GAAP) spending to support launches and pipeline advancement, along with unrealized equity investment losses of $196 million. Management highlighted a new $3.0 billion share repurchase authorization in April 2024, on top of $1.2 billion remaining under the prior program, signaling continued capital return alongside investment in innovation. Cash and marketable securities rose to $17.5 billion from $16.2 billion at year-end 2023, and free cash flow was $1.38 billion versus $1.19 billion a year earlier. Full-year 2024 guidance was mixed: GAAP and non-GAAP R&D were raised, GAAP SG&A floor was raised, and capital expenditure guidance was lowered to $780-880 million; the 2seventy bio acquisition costs were incorporated into the R&D outlook. Key pipeline catalysts include the linvoseltamab BLA decision (target action date August 22, 2024) and the odronextamab complete response letters, which cited only trial enrollment status as an approvability issue.

May 2, 2024 10-K

Regeneron Pharmaceuticals Annual Report, Year Ended Dec 31, 2023

Regeneron's FY2023 results show revenue of $13.12 billion, up about 8% from $12.17 billion in 2022, but net income fell 9% to $3.95 billion and diluted EPS dropped to $34.77 from $38.22. The decline reflects higher operating expenses, which rose 22% to $9.07 billion, driven by R&D up 24% to $4.44 billion and SG&A up 24% to $2.63 billion. Lower income tax expense (effective rate 5.9% versus 10.7%) partly cushioned the drop. Interest income surged to $496 million on higher rates, helping offset unrealized losses on equity securities. The core commercial concern is concentration and erosion in the ophthalmology franchise. U.S. EYLEA and the newly launched EYLEA HD fell 6% combined, and EYLEA's regulatory exclusivity expires May 17, 2024, opening the door to biosimilars. Management stated EYLEA HD's uptake is needed to offset EYLEA erosion, and that the degree of offset is uncertain. Dupixent, co-commercialized with Sanofi, is the main growth engine: Regeneron's share of antibody profits rose to $3.14 billion from $2.08 billion, and Dupixent's COPD filing and CSU complete response letter shape its near-term pipeline. Libtayo's global sales grew to $863 million. Balance sheet strength is substantial, with $16.2 billion in cash and marketable securities against $2.7 billion of debt and finance lease obligations. The company repurchased $2.2 billion of stock in 2023 and has $1.53 billion remaining under its authorization. Risks to note include a heavy reliance on two U.S. distributors (76% of gross product revenue), ongoing DOJ and False Claims Act matters tied to EYLEA and other products, and Amgen and biosimilar patent litigation. Capital expenditures are guided to $825 million to $950 million in 2024.

Feb 5, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Feb 2, 2024)

Regeneron's Q4 and full-year 2023 results, furnished under Item 2.02 via Exhibit 99.1, show a company growing its top line while absorbing heavy R&D and commercial investment. Q4 2023 total revenues rose 1% to $3.43 billion, but excluding Ronapreve (COVID-19 antibody sales recorded by Roche) revenues grew 14%. Full-year revenues increased 8% to $13.12 billion, or 12% excluding Ronapreve. Growth was driven largely by Dupixent, whose global net sales (recorded by Sanofi) rose 33% for the year to $11.59 billion. Regeneron's share of antibody profits from Dupixent flowed through Sanofi collaboration revenue, which increased 33% for the year. Profitability was weaker. GAAP diluted EPS fell 9% to $34.77 for 2023, and non-GAAP EPS fell 3% to $43.79. Q4 GAAP EPS was $10.19, which included a $0.21 hit from acquired IPR&D. U.S. EYLEA franchise sales declined 9% for the year, reflecting lower net price and volume, while the launch of EYLEA HD in August 2023 contributed $166 million. R&D spending rose 24% on a GAAP basis, and SG&A rose 24%. Higher interest income of $496 million and a very low effective tax rate (5.9% GAAP for the year) cushioned the results. Cash and marketable securities reached $16.2 billion, and free cash flow was $3.9 billion. For 2024, management guided to GAAP R&D of $4.82–$5.07 billion, GAAP SG&A of $2.89–$3.09 billion, and a GAAP effective tax rate of 8–10%. The company also announced the CFO's retirement and several pipeline and regulatory milestones, including an odronextamab FDA action date of March 31, 2024. Investors will likely focus on whether Dupixent and EYLEA HD can offset EYLEA erosion and whether rising operating costs translate into earnings growth.

Feb 2, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Jan 31, 2024)

Regeneron Pharmaceuticals, Inc. (REGN) has announced a planned succession in its finance leadership team. Effective February 5, 2024, following the filing of their 2023 Form 10-K, Christopher Fenimore will be appointed as Senior Vice President, Finance and Chief Financial Officer, succeeding the retiring Robert E. Landry. Concurrently, Jason Pitofsky will be promoted to Vice President, Controller. This transition is part of a previously disclosed CFO succession plan. Mr. Fenimore, with extensive experience within Regeneron and prior roles in the biotech and finance sectors, will see his 2024 base salary adjusted to $660,000 and received a significant equity award in December 2023 valued at $5 million. Mr. Pitofsky's appointment to Controller is a promotion from his previous role as VP, Accounting and Financial Reporting, with no immediate changes to his compensation. Investors can view this as a continuation of internal talent development and a structured handover of critical financial oversight.

Jan 31, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jan 8, 2024)

Regeneron (REGN) used its appearance at the 42nd J.P. Morgan Healthcare Conference on January 8, 2024 to furnish preliminary, unaudited fourth-quarter 2023 U.S. net product sales: approximately $123 million for EYLEA HD (aflibercept 8 mg), its first full quarter after FDA approval for wet AMD, DME and DR, and approximately $1.34 billion for the established EYLEA franchise. Combined U.S. EYLEA family sales were roughly $1.46 billion. The EYLEA HD launch is the central investor focus, as management argues it can become the next-generation standard of care in anti-VEGF therapy, citing early broad uptake, roughly two-thirds of eligible lives with coverage, and a permanent J-Code expected April 1, 2024. The filing also discloses a $30 million pre-tax acquired IPR&D charge in Q4 2023 tied to a payment to extend the Intellia Therapeutics collaboration. The charge is expected to reduce both GAAP and non-GAAP diluted EPS by about $0.21. Regeneron does not forecast such charges because their timing and size are uncertain, so investors should treat the reported figures as preliminary and subject to closing procedures. The accompanying presentation (Exhibit 99.1) is a broad 2024 strategic update covering the Dupixent COPD opportunity and its pending sBLA, Libtayo growth expected to exceed $1 billion in 2024, linvoseltamab and odronextamab regulatory milestones, CD28 costimulatory bispecifics, obesity and genetic medicine programs, and a 2024 milestone calendar. Because the Q4 figures are unaudited and the filing is largely a forward-looking presentation, the near-term catalysts are the EYLEA HD uptake trajectory, the odronextamab and linvoseltamab regulatory decisions, and the Dupixent COPD approval timing.

Jan 8, 2024 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Nov 2, 2023)

Regeneron reported third quarter 2023 total revenues of $3.36 billion, up 15% year over year, driven primarily by strong Dupixent performance flowing through the Sanofi collaboration (Sanofi collaboration revenue up 50% to $1.07 billion) and Libtayo growth of 62% on a global basis. GAAP diluted EPS fell to $8.89 from $11.66 (down 24%), but non-GAAP diluted EPS rose 4% to $11.59. The GAAP figure absorbed a $100 million acquired IPR&D charge tied to a development milestone for the ALN-APP program with Alnylam, worth about $0.77 per share, and a $100 million net unrealized loss on equity securities, which contrasted with a $254 million gain a year earlier. Interest income of $134 million partly offset these items. U.S. EYLEA net sales declined 11% to $1.45 billion as competition and lower net selling prices weighed on the franchise. The newly approved EYLEA HD contributed $43 million in its first partial quarter following its August 2023 FDA approval for wet AMD, diabetic macular edema, and diabetic retinopathy. Total net product sales were roughly flat at $1.79 billion. Management also raised the low end of several 2023 guidance ranges, lowering capital expenditure guidance to $660–$700 million and narrowing non-GAAP R&D and SG&A ranges. Regeneron repurchased $507 million of stock in the quarter and retains $1.8 billion of authorization. Pipeline and governance news included FDA priority review for odronextamab (target action date March 31, 2024) and for pediatric Dupixent in eosinophilic esophagitis (target date January 31, 2024), alongside a Complete Response Letter for Dupixent in chronic spontaneous urticaria requiring additional efficacy data. The company also completed the Decibel Therapeutics acquisition for $101 million upfront, announced that CFO Robert Landry will retire in February 2024, and named Christopher Fenimore as his successor.

Nov 2, 2023 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q3 Ended Sep 30, 2023

Regeneron Pharmaceuticals, Inc. reported a strong third quarter of 2023, driven by robust growth in key products like Dupixent and Libtayo, alongside collaboration revenues. Total revenues increased to $3.36 billion, a 14.5% rise year-over-year, with net income reaching $1.01 billion. The company also saw significant growth in its marketable securities portfolio and continued to execute its share repurchase program, returning capital to shareholders. Despite a slight decline in Eylea U.S. net product sales due to increased competition, the approval of Eylea HD in August 2023 provides a significant opportunity for future growth in the ophthalmology market. The company's R&D expenses increased, reflecting ongoing investment in its diverse pipeline, including advancements in oncology and immunology. Regeneron maintains a solid financial position with substantial cash and marketable securities, providing flexibility for future investments and strategic initiatives.

Nov 2, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Oct 5, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose an expected $100 million pre-tax acquired in-process research and development (IPR&D) charge for the third quarter of 2023. This charge is primarily related to a development milestone payment for the Phase 1 ALN-APP program in early-onset Alzheimer's disease, stemming from Regeneron's collaboration with Alnylam Pharmaceuticals, Inc. This IPR&D charge is anticipated to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.78 for the quarter. While this charge will impact reported earnings, it represents a milestone achievement in the company's research pipeline. Regeneron notes that these IPR&D charges are inherently unpredictable in timing and magnitude and are therefore not typically forecasted.

Oct 5, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Sep 8, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing significant changes within its board of directors and executive leadership. Notably, the company announced the retirement of its Chief Financial Officer, Robert E. Landry, who has served in that capacity since 2013. Mr. Landry plans to retire in February 2024, and the company has appointed Christopher Fenimore, currently Senior Vice President, Controller, as his successor, ensuring a smooth transition in financial leadership. In addition to the CFO transition, Regeneron has elected two new independent directors to its Board: Dr. Kathryn Guarini and Dr. David P. Schenkein. These appointments are intended to fill existing vacancies and strengthen the Board's expertise. The report also discloses the departure of Dr. Marc Tessier-Lavigne as a director due to potential conflicts arising from increased involvement with other companies. These leadership changes, while significant, are presented as strategic moves to ensure continued strong governance and financial oversight at Regeneron.

Sep 8, 2023 8-K

Regeneron Pharmaceuticals 8-K/A Report, Shareholder Vote Results (Sep 8, 2023)

This filing is an amendment to a previous 8-K report and serves to clarify Regeneron Pharmaceuticals, Inc.'s decision regarding the frequency of shareholder advisory votes on executive compensation. The company's Board of Directors, accepting the recommendation of its Compensation and Corporate Governance committees, has determined that these advisory votes will continue to be held annually. This decision follows a shareholder vote at the 2023 Annual Meeting of Shareholders held on June 9, 2023, where the option for a one-year frequency received a majority of the votes cast. The amendment, filed on September 7, 2023, with an event date of June 8, 2023, is a procedural update to formally disclose this outcome and the Board's subsequent confirmation.

Sep 8, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Aug 3, 2023)

Regeneron (REGN) reported second quarter 2023 results on August 3, 2023, with total revenues up 11% year over year to $3.16 billion and GAAP diluted EPS of $8.50 (up 14%). Non-GAAP diluted EPS was $10.24 (up 5%). Growth was driven by Sanofi collaboration revenue, which rose 39% to $944 million on higher Dupixent profit-sharing, while Dupixent global net sales (recorded by Sanofi) grew 33% to $2.79 billion. Offsetting this, U.S. EYLEA net sales fell 7% to $1.50 billion on lower net selling prices amid increased competition, and operating expenses rose sharply, with GAAP R&D up 37% and SG&A up 37%. The most important near-term item is the FDA Complete Response Letter for aflibercept 8 mg received in June 2023. The CRL was tied solely to inspection observations at third-party filler Catalent, not to clinical efficacy or safety. Regeneron expects to submit the required data by mid-August and anticipates FDA action in the third quarter of 2023. The company also reported two-year PHOTON data in DME, and the PULSAR wet AMD two-year data are still expected in the third quarter. Other items for investors include a discontinued enrollment in the REGN5678 plus full-dose Libtayo prostate cancer cohort after two immune-mediated Grade 5 adverse events, a 2025 readout for itepekimab COPD studies after passing an interim futility analysis, and a favorable Supreme Court ruling ending the Praluent patent dispute. The company raised its 2023 GAAP R&D and SG&A guidance ranges at the low end and lowered capital expenditure guidance. Cash and marketable securities were $15.3 billion, and the company repurchased $723 million of stock during the quarter with $2.3 billion remaining under its authorization.

Aug 3, 2023 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q2 Ended Jun 30, 2023

Regeneron Pharmaceuticals, Inc. (REGN) reported solid financial results for the second quarter and first half of 2023, demonstrating continued revenue growth driven primarily by Dupixent and Libtayo, which offset a decline in EYLEA sales in the US. Total revenues increased by 10.5% year-over-year for the first six months of 2023. Net income also saw an increase, reaching $1.79 billion for the first half of the year. The company's strong financial position is supported by a robust cash balance and significant investments in research and development, underscoring its commitment to pipeline expansion and innovation. The company is strategically navigating the competitive landscape for EYLEA, facing increased competition and awaiting regulatory decisions on its next-generation aflibercept 8 mg. However, the significant growth in Dupixent and Libtayo, along with progress in its robust pipeline of over 30 product candidates, positions Regeneron for sustained long-term growth. Investors should monitor upcoming regulatory decisions, especially for aflibercept 8 mg, and the continued commercial performance of key growth drivers like Dupixent.

Aug 3, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Bylaw Amendment (Jun 14, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 13, 2023, detailing key corporate governance actions and shareholder vote outcomes from its Annual Meeting held on June 9, 2023. The most significant governance change involves an amendment to the company's By-Laws to implement its previously disclosed Board leadership succession plan, allowing for the election of two Co-Chairs of the Board. Shareholders overwhelmingly approved routine matters, including the election of Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023, and the advisory vote on executive compensation. The company will continue with annual advisory votes on executive compensation. A shareholder proposal related to access to medicine in intellectual property protection was not approved.

Jun 14, 2023 10-Q

Regeneron Pharmaceuticals Quarterly Report for Q1 Ended Mar 31, 2023

Regeneron Pharmaceuticals, Inc. reported its first-quarter 2023 financial results, demonstrating revenue growth and a strong balance sheet. Total revenues increased to $3.16 billion, up from $2.97 billion in the same period last year, driven primarily by a significant increase in collaboration revenue, particularly from the Sanofi antibody collaboration. Net product sales saw a modest increase of $29 million to $1.67 billion, with notable growth in Libtayo and Evkeeza offsetting a decline in EYLEA U.S. sales. The company maintained a solid financial position with approximately $3.9 billion in cash and cash equivalents and over $11 billion in marketable securities. Research and development expenses increased significantly, reflecting continued investment in its robust pipeline, including advancements in immunology, inflammation, and oncology programs. The company also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.

May 4, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (May 4, 2023)

Regeneron's first quarter 2023 results showed total revenues up 7% year over year to $3.16 billion, driven primarily by Sanofi collaboration revenue (up 26% to $798 million) on higher Dupixent profit share, partly offset by a 6% decline in U.S. EYLEA net sales to $1.43 billion as higher sales-related deductions outweighed volume gains. GAAP diluted EPS fell 17% to $7.17 from $8.61, while non-GAAP diluted EPS declined 12% to $10.09, with both figures absorbing a $0.42 charge from acquired IPR&D, including a $45 million up-front payment to Sonoma Biotherapeutics. Operating expenses rose sharply, with GAAP R&D up 30% and SG&A up 34%, reflecting higher headcount and the assumption of worldwide Libtayo commercialization responsibilities. Management raised its 2023 GAAP R&D and SG&A guidance and lowered GAAP gross margin and tax rate guidance, while leaving non-GAAP R&D and SG&A unchanged. Cash and marketable securities reached $15.0 billion, and the company repurchased $694 million of stock in the quarter, with $3.05 billion remaining under its authorizations. Free cash flow fell to $1.19 billion from $1.96 billion a year earlier, as operating cash flow dropped to $1.37 billion from $2.10 billion. Pipeline news was mixed but notable. The Dupixent COPD Phase 3 trial met its primary and key secondary endpoints, with a 30% reduction in moderate or severe exacerbations, and the aflibercept 8 mg BLA is under FDA priority review with a June 27, 2023 target action date. A Dupixent chronic cold induced urticaria study failed and was discontinued. The company also announced that Chair P. Roy Vagelos will retire at the June 2023 annual meeting, after which Leonard Schleifer and George Yancopoulos are planned to become co-chairs.

May 4, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Executive Changes (Apr 17, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant leadership transition in its upcoming 2023 Annual Meeting of Shareholders. Dr. P. Roy Vagelos, the current Chair of the Board, has decided not to stand for re-election. This marks the end of his tenure, during which he will continue to serve until the conclusion of the meeting on June 9, 2023. The company has stated that Dr. Vagelos's decision was not due to any disagreements regarding the company's operations or policies.

Apr 17, 2023 8-K

Regeneron Pharmaceuticals 8-K Report, Financial Results (Apr 10, 2023)

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 10, 2023, to disclose an expected acquired in-process research and development (IPR&D) charge for the first quarter of 2023. This charge is primarily related to an upfront payment for their collaboration and license agreement with Sonoma Biotherapeutics, Inc. The company anticipates a pre-tax IPR&D charge of approximately $56 million, which is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $0.42 for the quarter. While this charge is a notable event impacting short-term profitability per share, investors should note that such IPR&D charges are inherently unpredictable and are not typically forecasted by the company. The disclosed figures are preliminary estimates and are subject to finalization of the company's financial closing procedures. Investors should monitor future filings for finalized financial results and strategic updates regarding the Sonoma Biotherapeutics collaboration.

Apr 10, 2023